EFFECT OF GEMCABENE ON INSULIN SENSITIVITY IN NONDIABETIC, OBESE SUBJECTS

Background: Gemcabene (GEM), an ApoC-III and CRP modulator, showed significant LDL-C, ApoB, TG and hsCRP lowering and trends of glucose lowering in dyslipidemic subjects. In preclinical studies, 3T3L1 differentiated adipocytes treated with 100µM GEM plus insulin resulted in a 25% increase in [14C]